T1G3 bladder cancer--the case for TUR and BCG.
Miller
K
K
Department of Urology, University Medical Center Benjamin Franklin, Berlin, Germany. miller@ukbf.fu-berlin.de
D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods*; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy
D001500:BCG Vaccine